APX2009 belongs to the second generation of APE1/REF-1 redox inhibitors, whose studies reported anticancer properties in treating colon, bladder, pancreatic, and prostate cancer (5-, 7,14). This evidence concerns the gene APEX1 and prostate carcinoma.